Background
==========

Familial Mediterranean Fever (FMF) is a hereditary autoinflammatory disease characterized by unprovoked, self-limiting attacks of fever and serositis [@B1], diagnosed using clinical criteria [@B2]. It is associated with mutations in the MEFV-gene encoding for the pyrin protein [@B3], [@B4]. Lifelong prophylactic administration of colchicine is the therapy of choice [@B5], [@B6], which can reduce FMF attacks [@B7]-[@B9] and prevents the development of amyloidosis [@B10], the most severe long-term complication of FMF. However, subclinical inflammation may persist in clinically stable FMF patients [@B11].

As inflammatory processes underly the development of atherosclerosis, which can contribute to ischemic heart disease and atrial fibrillation [@B12], it has been suggested that FMF might promote atherogenesis secondary to a persisting inflammatory state [@B13]. Various indirect markers of atherosclerosis have already been associated with diagnosis of FMF and include increased intima-media thickness [@B14], reduced vascular flow-mediated dilation [@B15] and reduced coronary flow reserve assessed by transthoracic Doppler echocardiography [@B16].

Recently, two electrocardiographic (ECG) indices have been reported to be altered in FMF patients: P wave dispersion (Pdisp), which reflects homogeneity of atrial conduction, and QT dispersion (QTdisp), is a measure which can indicate abnormalities of ventricular repolarization.

A prolonged Pdisp was described for adult FMF patients in Turkey [@B17], which is a known predictor for atrial fibrillation (AF) [@B18], one of the most common cardiac rhythmic disorders, and one associated with adverse outcomes [@B19].

Increased QTdisp [@B20] and a positive correlation of QTdisp with C-reactive protein (CRP) has also been described in Turkish FMF patients [@B21]. Increased QTdisp is is reported to directly correlate with susceptibility to complex ventricular rhythm disorders and sudden cardiac death [@B22]-[@B24]. ECG monitoring is cheap, non-invasive and widely available, and may provide an easy way to monitor for cardiac abnormalities.

It is known that for FMF the course of disease and clinical outcomes vary according to the country of residence, including for example, the prevalence of amyloidosis or the severity of disease [@B25], [@B26]. Therefore, whilst studies describing electrocardiographic abnormalities in FMF patients living in countries where FMF is endemic exist, firstly they show conflicting results, and secondly, the results cannot be extrapolated to FMF patients from high prevalence that are resident in countries with low FMF prevalence. Currently, there are no studies describing ECG findings in adult FMF patients of Turkish ancestry living in Germany.

The aim of our study was therefore to compare Pdisp and QTdisp findings in FMF patients of Turkish descent living in Germany, with findings in a healthy control group in order to see whether it would make sense to include an ECG - screening into the routine workup of FMF patients.

Method
======

Patients and controls
---------------------

Consecutive adult patients (age ≥18 years) with FMF according to the simplified Livneh criteria [@B2] were prospectively included into the study at the University Medical Centre of the Ruhr-University Bochum, Herne. Patients reporting symptoms of an FMF attack within seven days prior to their presentation were excluded from the study. Age-matched healthy adults served as controls. All study participants were of Turkish ancestry. Informed consent was obtained prior to study inclusion. The study was approved by the ethics committee of the medical faculty of the Ruhr-University Bochum, Germany (study register number: 3772-10).

A structured interview and a clinical examination were performed by native Turkish speaking medical staff. Erythrocyte sedimentation rate (ESR), CRP and serum amyloid A (SAA) were assessed from blood or serum obtained at study inclusion. Disease severity in FMF patients was scored using the Pras et al. score [@B27].

Electrocardiography
-------------------

A 12 - lead ECG was recorded during 5 seconds using a MAC 1200 ST (GE Medical systems information technology, GE, Providence, RI, USA) at a paper speed of 50 mm / sec and a gain of 10 mm per mV with the patient lying supine. ECG electrodes were placed in the standard positions [@B28]. During ECG recording patients were not speaking, but breathing freely. Two physicians experienced in the interpretation of ECG\'s and blinded to whether study participants were in the FMF patient or control groups performed the ECG measurements using calipers and a magnifying lens (10-fold magnification). Assessment of each measurement was repeated three times by each physician and the average value was used for analysis. **Table [1](#T1){ref-type="table"}** summarizes the definitions for the different measurements performed. We excluded patients in whom measurement of P wave or QT interval was not possible.

Statistical analysis
--------------------

Statistical analyses were performed using SPSS (version 20.0; SPSS Inc. Chicago, IL, USA). Continuous variables are depicted as mean ± standard deviation (SD), and compared using the Student T test. Categorical variables are depicted as number and percentage, and analysed using Fisher\'s exact test. Association between ECG measurements and biochemical markers of inflammation was assessed using Pearson\'s correlation coefficient. A two-tailed p value less than 0.05 was considered statistically significant. Intra-class correlation coefficients were calculated to determine intra- and inter-rater reliability for ECG measurements.

Results
=======

We enrolled 30 patients with FMF and 37 controls in the study and found the following ethnic characteristics: 13 patients (43.3%) vs. 20 (54.1%) controls were born in Turkey (p = 0.464). Their age at immigration was 15.2 ± 10.8 vs. 12.4 ± 8.5 years respectively (p = 0.412). 17 FMF patients (56.7%) and 17 controls (45.9%) were born in Germany. Two of those FMF patients had one parent born in Turkey and one parent born in Germany (but of Turkish ancestry). The rest of the patients and all of the controls born in Germany had two parents that were born in Turkey.

The clinical and laboratory characteristics of the study participants are summarized in **table [2](#T2){ref-type="table"}**. None of the study participants had pre-existing diagnoses or symptoms of heart disease. Of the 30 patients with FMF, 26 were on regular prophylactic colchicine treatment. Of the remaining four patients, two had never taken colchicine, and two had discontinued the treatment earlier. Disease related characteristics of the patients with FMF are shown in **table [3](#T3){ref-type="table"}**. ECG characteristics of the study participants are shown in **table [4](#T4){ref-type="table"}**. There was no significant correlation between Pdisp or QTdisp with any of the biochemical markers of inflammation (ESR, CRP, SAA; data not shown), and also Pdisp and QTdisp did not correlate with the Pras disease severity score [@B27] in patients with FMF patients.

As a subgroup analysis, we compared Pdisp, QTdisp and cQTdisp between the 26 FMF patients taking long-term colchicine and the 4 FMF patients who weren\'t. Secondly we analysed these two groups of FMF patients and healthy controls concerning Pdisp, QTdisp and cQTdisp. None of these comparisons yielded differences reaching statistical significance (data not shown).

For the longest QT interval (QT max) in all leads intra class correlation coefficient (ICC) was 0.93 for observer 1 and 0.94 for observer 2. ICC between the mean QTmax obtained by both observers was 0.99.

Discussion
==========

Our study assesses markers of cardiac involvement in FMF patients living in Germany. No differences in Pdisp, QTdisp and cQTdisp were found between FMF patients and controls. We also did not find a significant correlation between Pdisp or QTdisp and any of the biochemical markers of inflammation studied.

Our data concerning homogeneity of atrial conduction, or Pdisp, in patients and controls are in line with two previous studies [@B29], [@B30], though two other studies do report an association between CRP and Pdisp, [@B17], [@B31], as shown summarized in **Table [5](#T5){ref-type="table"}.** In the literature there is evidence for a link between inflammation and an elevated Pdisp from hypertensive patients with arterial hypertension [@B32], [@B33], while an elevated Pdisp can also be a predictor of atrial fibrillation [@B18]. Data from a long-term follow up of FMF patients concerning the occurrence of atrial arrhythmias is lacking so far. An additional explanation for the varying results might be Pdisp varies even within healthy subjects depending on the method of measurement and the population chosen. However, the method chosen in our study is the best available.

We also found no difference in QTdisp or cQTdisp between patients with FMF and controls, though literature regarding these indices are also conflicting. **Table [6](#T6){ref-type="table"}**summarises the studies supporting [@B34]-[@B37] and opposing our findings [@B20], [@B21].

Different inflammatory rheumatic diseases are known to increase QTdisp including rheumatoid arthritis (cQTdisp patients: 40.2 ± 14.4 ms vs. controls: 23.8 ± 6.1 ms) [@B38], ankylosing spondylitis (cQTdisp patients: 60.3 ± 16.1 ms vs. controls: 39.4 ± 10.7 ms) [@B39] and systemic lupus erythematosus (QTdisp patients: 55.2 ± 24.7 ms vs. controls: 20.7 ± 5.3 ms) [@B40].

So far, ECG measurements of atrial conduction and cardiac repolarization have not been proven to be useful as indirect markers of cardiovascular involvement in identifying increased risk of atrial or ventricular arrhythmias, in patients with FMF. Only two studies have evaluated the long-term outcome of FMF patients since colchicine became an accepted treatment. A cohort of over 1.2 million Israeli army recruits followed for more than 20 years showed an increased mortality in FMF patients compared to controls, with renal amyloidosis responsible for death in 40% of FMF patients [@B41]. In another cohort study from Turkey, amyloidosis was responsible for 50% of deaths among FMF patients during a median follow-up time of 6 years, and amyloidosis was the only independent predictor of mortality [@B42]. Colchicine has been proven to be useful in the secondary prophylaxis of vascular events in patients with coronary heart disease [@B43], atrial fibrillation [@B44] as well as in the prevention of in-stent restenosis in diabetic patients [@B45]. One might therefore speculate that colchicine, which is currently prescribed to most FMF patients, may antagonize some of the detrimental effects of chronic inflammation - as they are known for other inflammatory diseases - on the cardiovascular system.

Study limitations
-----------------

Although reliable data on the prevalence of FMF in Germany are lacking FMF is thought to be a rare disease in Germany. The incidence among children ≤ 16 years is estimated to range between 25-50 newly diagnosed FMF cases per year leading to a number of about 400 to 800 affected children ≤16 years (300-600 of them with a Turkish ancestry) [@B46]. The size of our study thus results from the scarcity of FMF patients in Germany.

Previous studies dealing with electrocardiographic markers in FMF included only patients on regular colchicine treatment. In the present study 4 of the 30 FMF patients (13,3%) were not regularly taking colchicine at the time of study inclusion. The subgroup of FMF patients not regularly taking colchicine show no difference in Pdisp or QTdisp. However, it is too small (n=4) to exclude a difference with sufficient power.

Our study did not include echocardiographic assessment of study participants. We could thus not verify the findings of previous studies dealing with atrial conduction in FMF. Inter-atrial and intra-atrial electromechanical delay (measured as the time from the onset of the P wave on surface ECG to the beginning of the A wave on tissue Doppler echocardiography) has been reported to be prolonged in FMF patients compared to healthy controls [@B17] and some echocardiographic markers of diastolic function might be altered in FMF patients [@B31]. Of all the studies dealing with ventricular repolarisation in FMF only two included an electrocardiographic assessment showing no significant difference between patients and controls [@B21], [@B37].

In the present study the diagnosis of FMF was confirmed among patients using the simplified Livneh criteria. These criteria have been reported to yield a sensitivity and specificity ≥ 96% [@B2]. FMF was also clinically excluded among controls. A routine genetic assessment of the MEFV Gene was not part of the study. Thus genetic data was only available for some FMF patients and for none of the controls. Since the proportion of people heterozygous for one of the MEFV mutations typical for FMF among Turkish people might be as high as 20% [@B47] we cannot exclude the presence of MEFV heterozygotes among the controls.

Future work of interest would be a multicentre study to augment sample size and minimize selection bias as well as a long-term study centered on cardiovascular involvement of FMF. Further studies should also include an echocardiographic assessment and a screening of the MEFV - gene in patients and controls to evaluate other cardiovascular markers und to assess the importance of the MEFV genotype.

Conclusion
==========

As an autoinflammatory disease FMF is associated with a persisting inflammatory state. Since atherosclerosis and cardiovascular events have been linked to inflammation the question is whether FMF patients are prone to a higher cardiovascular risk. So far this has not been studied in a country with a low prevalence of FMF.

In our study on FMF patients and healthy controls living in Germany we have examined two ECG - markers that are increased in cardiac atrial or ventricular rhythmic disorders: Pdisp and QTdisp. We have found no association of FMF with Pdisp or QTdisp. Furthermore there was no correlation of Pdisp or QTdisp with biochemical markers of inflammation.

The absence of an association between FMF and Pdisp or QTdisp as markers of cardiac arrhythmias found in our study is in line with reports on the long-term prognosis of FMF patients. These reports indicate that renal amyloidosis but not coronary heart disease is the only significant predictor of mortality.

Since data on ECG indices in FMF are conflicting future studies will have to further elucidate the relationship between cardiovascular disease and autoinflammation.

We are indebted to Dr. Atilla Cintosun, Herne for his assistance in patient recruitment.

###### 

Definition of ECG measurements

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ECG feature                       Definition used in our study
  --------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  RR interval (RR)                  Duration between the peak of two R-waves

  P wave duration (P)               Duration of the positive or negative wave between the first visible upward or downward deflection (depending on the waveform) from baseline and the subsequent return to baseline

  Minimum P wave duration (Pmin)    Shortest P wave in all ECG leads

  Maximum P wave duration (Pmax)    Longest P wave in all ECG leads

  P wave dispersion (Pdisp)         Difference between Pmin and Pmax

  QT interval (QT)                  Duration between the first visible downward deflection from baseline after the end of the P wave and the return to baseline after the T wave

  Minimum QT interval (QTmin)       Shortest QT interval in all ECG leads

  Maximum QT interval (QTmax)       Longest QT interval in all ECG leads

  QT interval dispersion (QTdisp)   Difference between QTmin and QTmax

  Corrected QT interval (cQT)       Rate correction of QT interval was performed with the use of the Bazett Formula [@B48] below:\
                                    cQT = QT/√RR in s\
                                    Corrected intervals (cQTmin, cQTmax, cQTdisp) were calculated in analogy.
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Clinical and laboratory characteristics of study participants

  ----------------------------------------------------------------------------
                                 FMF patients\   Controls\      Significance
                                 (n = 30)        (n = 37)       
  ------------------------------ --------------- -------------- --------------
  Female subjects n (%)          16 (53.3)       20 (54.1)      p= 1.00

  Age (years)                    33.5 ± 10.2     33.7 ± 10.6    p= 0.94

  Body length (cm)               167.7 ± 8.7     169.0 ± 11.1   p= 0.62

  Body weight (kg)               73.8 ± 12.4     78.7 ± 18.9    p= 0.21

  Body mass index (BMI)          26.2 ± 3.9      27.3 ± 4.8     p= 0.30

  ESR (mm/1^st^ hour), N: \<20   23.7 ± 14.3     16.1 ± 13.3    **p= 0.029**

  CRP (mg/dl), N: \<0.5          0.728 ± 0.92    0.262 ± 0.41   **p= 0.01**

  SAA (mg/dl), N: \<0.5          3.14 ± 4.82     0.37 ± 0.26    **p\< 0.01**
  ----------------------------------------------------------------------------

n: number, p: significance; a p \<0.05 is written in bold letters; ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, SAA: serum amyloid A

###### 

Disease related characteristics of FMF patients

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                         All FMF patients\   FMF on colchicine\   Significance treated\   FMF without colchicine (n = 4)
                                                                         (n = 30)            (n = 26)             vs. untreated           
  ---------------------------------------------------------------------- ------------------- -------------------- ----------------------- --------------------------------
  Age (years)                                                            33.5 ± 10.2         32.3 ± 10.3          p= 0.09                 41.5 ± 5.6

  Age at FMF onset (years)                                               11.4 ± 8.2          10.4 ± 6.7           p= 0.11                 17.5 ± 14.7

  Duration of disease (years)                                            21.7 ± 9.3          21.4 ± 8.4           p= 0.61                 24.0 ± 15.4

  Pras score [@B27]                                                      6.93 ± 2.00         7.15 ± 2.03          p= 0.13                 5.5 ± 1.00

  Delay from disease onset to initiation of colchicine therapy (years)   11.7 ± 7.6          11.7 ± 7.6           n.a.                    n.a.

  Colchicine dosage (mg/day)                                             1.22 ± 0.72         1.40 ± 0.57          n.a.                    n.a.

  ESR (mm/1^st^ hour), N: \<20                                           23.7 ± 14.3         21.1 ± 12.2          **0.008**               40.8 ± 16.8

  CRP (mg/dl), N: \<0.5                                                  0.73 ± 0.92         0.60 ± 0.82          **0.042**               1.59 ± 1.19

  SAA (mg/dl), N: \<0.5                                                  3.14 ± 4.82         2.70 ± 4.71          0.220                   6.40 ± 5.24
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------

n: number, p: significance; n.a.: not applicable; a p \<0.05 is written in bold letters.

###### 

Electrocardiographic characteristics of the study participants

  --------------------------------------------------------------------------
  ECG feature                 FMF patients\   Controls\       Significance
                              (n = 30)        (n = 37)        
  --------------------------- --------------- --------------- --------------
  RR (ms)                     814.4 ± 150.2   799.9 ± 132.7   p= 0.68

  Heart rate (beats/minute)   76.0 ± 13.4     77.1 ± 13.1     p= 0.74

  Pmin (ms)                   71.1 ± 9.5      66.4 ±11.7      p= 0.08

  Pmax (ms)                   114.7 ± 10.7    113.5 ± 10.1    p= 0.63

  Pdisp (ms)                  43.7 ± 11.9     47.1 ± 11.2     p= 0.23

  QTmin (ms)                  340.0 ± 25.7    335.1 ± 24.5    p= 0.43

  cQTmin (ms)                 379.5 ± 24.3    377.4 ± 29.8    p= 0.75

  QTmax (ms)                  405.9 ± 23.5    402.7 ± 24.7    p= 0.59

  cQTmax (ms)                 453.4 ± 24.8    453.4 ± 28.9    p= 0.99

  QTdisp (ms)                 65.9 ± 12.3     67.6 ± 12.7     p= 0.58

  cQTdisp (ms)                73.9 ± 15.0     76.0 ± 13.3     p= 0.55
  --------------------------------------------------------------------------

The abbreviations for the ECG features are described in **table [1](#T1){ref-type="table"}**. n: number, a p\<0.05 is written in bold letters, ms: milliseconds.

###### 

Summary of studies evaluating P wave dispersion in FMF patients

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author\            Characteristics of FMF patients   Group affiliation   Number        Age (y)\      Pdisp (ms)\   Significance\     Other results
  Publication year\                                                                            mean ± SD     mean ± SD     Pdisp             
  Country\                                                                                                                                   
  (Reference)                                                                                                                                
  ------------------------ --------------------------------- ------------------- ------------- ------------- ------------- ----------------- -------------------------
  Acar, A, 2009\           in attack-free interval\          FMF                 33            28.4 ± 12.5   42.8 ± 7.9    **p \< 0.0101**   CRP and Pdisp correlate
  Turkey [@B17]            all on colchicine                                                                                                 

  Controls                 33                                28.5 ± 12.1         35.3 ± 6.1                                                  

  Nussinovitch, N, 2011\   in attack-free interval\          FMF                 26            32.2 ± 13.8   28.8 ± 9.5    p ≥ 0.05          
  Israel [@B29]            all on colchicine\                                                                                                
                           no proteinuria                                                                                                    

  Controls                 28                                32.3 ± 14.1         28.9 ± 10                                                   

  Nussinovitch, U, 2011\   in attack-free interval\          FMF                 16            49.7 ± 14.9   34.2 ± 10.2   p ≥ 0.05          
  Israel [@B30]            biopsy-proven amyloidosis\                                                                                        
                           all on colchicine                                                                                                 

  Controls                 16                                43.8 ± 14.1         31.2 ± 9.8                                                  

  Arslan, D, 2013\         in attack-free interval\          FMF                 26            10.8 ± 2.8    61.9 ± 20.8   **p \<0.01**      CRP and Pdisp correlate
  Turkey [@B31]            all on colchicine\                                                                                                
                           no proteinuria                                                                                                    

  Controls                 25                                9.9 ± 2.8           32.6 ± 10.2                                                 
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------

ms: milliseconds; a p\<0.05 is written in bold letters; the abbreviations for the ECG features are described in **table [1](#T1){ref-type="table"}**.

###### 

Summary of studies evaluating QT wave dispersion in FMF patients

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author\            Characteristics of FMF patients   Group affiliation   Number        Age\          cQTdisp (ms)\   Significance\   Other results
  Publication year\                                                                            mean ± SD     mean ± SD       cQTdisp         
  Country\                                                                                                                                   
  (Reference)                                                                                                                                
  ------------------------ --------------------------------- ------------------- ------------- ------------- --------------- --------------- -------------------------------------------------
  Akcay, A, 2009\          in attack-free interval           FMF                 50            29.4 ± 11.8   40.4 ± 13.5     **p \< 0.01**   cQTdisp correlates with CRP and ESR
  Turkey [@B21]                                                                                                                              

  Controls                 50                                31.3 ± 11.9         21.9 ± 12.4                                                 

  Nussinovitch, N, 2010\   in attack-free interval\          FMF                 32            35.3 ± 16.9   51.4 ± 12.0     p ≥ 0.05        
  Israel [@B35]            all on colchicine\                                                                                                
                           no amyloidosis                                                                                                    

  Controls                 37                                34 ± 13.7           49.7 ± 10.5                                                 

  Topal, F, 2011\          in attack-free interval           FMF                 38            32.8 ± 11.0   33.6 ± 15       p ≥ 0.05        
  Turkey [@B36]                                                                                                                              

  Controls                 35                                28.1 ± 9.1          35.5 ± 19.2                                                 

  Canpolat, U, 2012\       in attack-free interval\          FMF                 38            34.4 ± 10.2   76.6 ± 12.6     **p \< 0.01**   QTdisp correlates with disease duration and CRP
  Turkey [@B20]            all on colchicine\                                                                                                
                           no amyloidosis                                                                                                    

  Controls                 34                                33.2 ± 9.3          52.4 ± 11.7                                                 

  Koca, B, 2012\           children with FMF                 FMF                 69            10.8 ± 2.9    64 ± 21.4       p = 0.26        
  Turkey [@B37]                                                                                                                              

  Controls                 71                                9.9 ± 2.8           59.7 ± 24                                                   

  Nussinovitch, U, 2012\   in attack-free interval\          FMF                 22            36.3 ± 10.5   46.0 ± 13.5     p ≥ 0.05        
  Israel [@B34]            all on colchicine but\                                                                                            
                           non-responsive to colchicine\                                                                                     
                           no proteinuria                                                                                                    

  Controls                 22                                34.0 ± 13.1         45.3 ± 7.9                                                  

  Nussinovitch, U, 2012\   in attack-free interval\          FMF                 18            50.2 ± 14.2   40.6 ± 16.4     p ≥ 0.05        
  Israel [@B49]            biopsy-proven amyloidosis\                                                                                        
                           all on colchicine                                                                                                 

  Controls                 18                                44.0 ± 13.9         40.7 ± 13.2                                                 
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ms: milliseconds; a p\<0.05 is written in bold letters; the abbreviations for the ECG features are described in **table [1](#T1){ref-type="table"}**.
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